Creative Biolabs Presents Upgraded CRO Service – Product Facilitating Toxoplasma Antibody Research
(YorkPedia Editorial):- New York City, New York Dec 27, 2022 (Issuewire.com) – In the United States, it is estimated that 11% of the population 6 years and older have been infected with Toxoplasma according to the Centers for Disease Control and Prevention (CDC). Although some medicines have come into the market, research on the discovery of alternative treatment methods is still going on as the number of parasite species resistant to off-the-shelf drugs is increasing.
Realizing the urgent need for finding novel anti-parasite drugs and understanding the great potential of antibody therapeutics, Creative Biolabs has established the AntInfect Platform to offer antibody discovery services targeting Toxoplasma.
More on YorkPedia:
- Bringing the Authentic Music of R&B the Recertified Teenager Releases New Track ‘The Groove’
- The North Carolina Music Band Apollo Craven Is Spreading Its Charm with Their Soundtracks
- Learn How to Measure Press Release Success in 11 Simple Ways
- Stay Updated about the International Music Industry with Daily Music Roll’s Music News
- Get Nostalgic with the Album ‘To Love Somebody…’ by O’Neill Fernandes
The innovative AntInfect Platform integrates antigen-specific B lymphocytes cytometry technology, hybridoma-based antibody screening technology, phage display-based antibody screening, phage display-based epitope mapping, and Magic sequencing.
Proficient in all functions of this five-star platform, the scientist team at Creative Biolabs guarantees precise analysis of the sequences of epitope-based antigens with single and combined antigens as capturers. The service covers potential antibody targets for Toxoplasma, such as surface protein SAG1 and its related sequence family (SRS), SAG2, and SAG3.
In addition, for Toxoplasma diagnosis and treatment research, a product, Human Anti-Toxoplasma IgD Antibody Competitive ELISA Kit-NGK-457 (For Research Use Only), has been put on sale after in-house verification. This product is for the in vitro determination of the Human Anti-Toxoplasma IgD Antibody in the samples of serum, plasma, cell culture supernatant, body fluid, and tissue homogenates. It is highly sensitive and available for the detection of IgD antibodies as low as 1.0 pg/mL.
“We never forget our mission to provide convenience to our clients and to have a significantly positive impact on global health. In order to achieve this goal, we will exert to explore more products and services to meet the market demands,” said Bella Smith from the marketing team at Creative Biolabs.
The AntInfect Platform also covers other parasites, such as Brugia, Cryptosporidium, Eimeria, Fasciola, Leishmania, Neospora, Plasmodium, Schistosoma, Strongyloides, Taenia, and Trypanosoma. Please feel free to check the website for detailed solutions and fill out the inquiry form to connect with an expert.
About Creative Biolabs
As a leading custom service provider in antibody development and engineering, Creative Biolabs has established cutting-edge technologies to support functional biomolecule development for infectious diseases. The service portfolio is comprised of anti-infective antibody and peptide discovery, as well as small molecule drug discovery for a wide range of virus, bacterial, and parasite infections, covering research, diagnostic and therapeutic purposes.
(YorkPedia Editorial):- New York City, New York Dec 27, 2022 (Issuewire.com) – In the United States, it is estimated that 11% of the population 6 years and older have been infected with Toxoplasma according to the Centers for Disease Control and Prevention (CDC). Although some medicines have come into the market, research on the discovery of alternative treatment methods is still going on as the number of parasite species resistant to off-the-shelf drugs is increasing.
Realizing the urgent need for finding novel anti-parasite drugs and understanding the great potential of antibody therapeutics, Creative Biolabs has established the AntInfect Platform to offer antibody discovery services targeting Toxoplasma.
The innovative AntInfect Platform integrates antigen-specific B lymphocytes cytometry technology, hybridoma-based antibody screening technology, phage display-based antibody screening, phage display-based epitope mapping, and Magic sequencing.
Proficient in all functions of this five-star platform, the scientist team at Creative Biolabs guarantees precise analysis of the sequences of epitope-based antigens with single and combined antigens as capturers. The service covers potential antibody targets for Toxoplasma, such as surface protein SAG1 and its related sequence family (SRS), SAG2, and SAG3.
In addition, for Toxoplasma diagnosis and treatment research, a product, Human Anti-Toxoplasma IgD Antibody Competitive ELISA Kit-NGK-457 (For Research Use Only), has been put on sale after in-house verification. This product is for the in vitro determination of the Human Anti-Toxoplasma IgD Antibody in the samples of serum, plasma, cell culture supernatant, body fluid, and tissue homogenates. It is highly sensitive and available for the detection of IgD antibodies as low as 1.0 pg/mL.
“We never forget our mission to provide convenience to our clients and to have a significantly positive impact on global health. In order to achieve this goal, we will exert to explore more products and services to meet the market demands,” said Bella Smith from the marketing team at Creative Biolabs.
The AntInfect Platform also covers other parasites, such as Brugia, Cryptosporidium, Eimeria, Fasciola, Leishmania, Neospora, Plasmodium, Schistosoma, Strongyloides, Taenia, and Trypanosoma. Please feel free to check the website for detailed solutions and fill out the inquiry form to connect with an expert.
About Creative Biolabs
As a leading custom service provider in antibody development and engineering, Creative Biolabs has established cutting-edge technologies to support functional biomolecule development for infectious diseases. The service portfolio is comprised of anti-infective antibody and peptide discovery, as well as small molecule drug discovery for a wide range of virus, bacterial, and parasite infections, covering research, diagnostic and therapeutic purposes.
This article was originally published by IssueWire. Read the original article here.
